Cover Image

Ten reasons why A1C should not be used as a screening tool for T2DM

Screening of a disease can be understood as detecting a disease in an individual before clinical symptoms are apparent. In case of diabetes mellitus, as of now, the preferred screening test is still fasting blood sugar (FBS). Glycated hemoglobin (A1C) however, did make its way into guidelines as a d...

Full description

Saved in:
Bibliographic Details
Main Author: Shahar, Mohammad Arif
Format: Conference or Workshop Item
Language:English
Published: 2017
Subjects:
R Medicine (General)
RC Internal medicine
Online Access:http://irep.iium.edu.my/58564/1/Debate%20HbA1C.pdf
http://irep.iium.edu.my/58564/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.iium.irep.58564
record_format dspace
spelling my.iium.irep.585642017-10-02T01:08:08Z http://irep.iium.edu.my/58564/ Ten reasons why A1C should not be used as a screening tool for T2DM Shahar, Mohammad Arif R Medicine (General) RC Internal medicine Screening of a disease can be understood as detecting a disease in an individual before clinical symptoms are apparent. In case of diabetes mellitus, as of now, the preferred screening test is still fasting blood sugar (FBS). Glycated hemoglobin (A1C) however, did make its way into guidelines as a diagnostic tool apart from its usual monitoring role. A1C is use for diagnosis rather than screening. A1C is an “index” measurement of non-enzymatic glycated hemoglobin against hemoglobin level. Therefore, there are conditions in which A1C can be falsely elevated or reduced. In patients with chronic kidney disease, carbamylated hemoglobin interferes with the assay and cause falsely elevated A1C. Conditions in which the life span of red blood cells is shortened, A1C readings are falsely lowered. In iron deficiency anemia, which is a common condition in developing countries, A1C is falsely elevated. However in those who are taking iron supplement, A1C is falsely lowered. In fact, the biology of A1C in non-diabetic individuals varies. In term of performance as a screening tool for diabetes, A1C only agrees with fasting blood sugar (FBS) about 25% of the time, and with oral glucose tolerance test (OGTT) 33% of the time. A study had shown that A1C misses 60% of diabetes cases diagnosed with OGTT. Finally, different cut-off point of A1C gives different sensitivity and specificity, whereby higher A1C improves specificity and lower improves sensitivity. One study found HbA1c of ≥ 6.5% had a sensitivity and specificity of 44% and 79%, respectively. Even guidelines could not agree on a single cut-off value for the diagnosis of type 2 diabetes mellitus. The American Diabetic Association uses an A1C cut-off value of 6.5% while the recent Malaysian Clinical Practice Guidelines on the Management of Type 2 Diabetes Mellitus uses 6.3% for diagnosis. Lastly, although a study in the UK demonstrated that screening using A1C is more cost-effective than FBS in Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) cohort, generalization should not be made for our population, given the differences in prevalence of diabetes, age group, cut-off value of A1C, the cost and availability of the test locally. 2017-07 Conference or Workshop Item REM application/pdf en http://irep.iium.edu.my/58564/1/Debate%20HbA1C.pdf Shahar, Mohammad Arif (2017) Ten reasons why A1C should not be used as a screening tool for T2DM. In: 8th National Diabetes Conference 2017, 28th July-30th July 2017, Subang USJ, Selangor. (Unpublished)
institution Universiti Islam Antarabangsa Malaysia
building IIUM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider International Islamic University Malaysia
content_source IIUM Repository (IREP)
url_provider http://irep.iium.edu.my/
language English
topic R Medicine (General)
RC Internal medicine
spellingShingle R Medicine (General)
RC Internal medicine
Shahar, Mohammad Arif
Ten reasons why A1C should not be used as a screening tool for T2DM
description Screening of a disease can be understood as detecting a disease in an individual before clinical symptoms are apparent. In case of diabetes mellitus, as of now, the preferred screening test is still fasting blood sugar (FBS). Glycated hemoglobin (A1C) however, did make its way into guidelines as a diagnostic tool apart from its usual monitoring role. A1C is use for diagnosis rather than screening. A1C is an “index” measurement of non-enzymatic glycated hemoglobin against hemoglobin level. Therefore, there are conditions in which A1C can be falsely elevated or reduced. In patients with chronic kidney disease, carbamylated hemoglobin interferes with the assay and cause falsely elevated A1C. Conditions in which the life span of red blood cells is shortened, A1C readings are falsely lowered. In iron deficiency anemia, which is a common condition in developing countries, A1C is falsely elevated. However in those who are taking iron supplement, A1C is falsely lowered. In fact, the biology of A1C in non-diabetic individuals varies. In term of performance as a screening tool for diabetes, A1C only agrees with fasting blood sugar (FBS) about 25% of the time, and with oral glucose tolerance test (OGTT) 33% of the time. A study had shown that A1C misses 60% of diabetes cases diagnosed with OGTT. Finally, different cut-off point of A1C gives different sensitivity and specificity, whereby higher A1C improves specificity and lower improves sensitivity. One study found HbA1c of ≥ 6.5% had a sensitivity and specificity of 44% and 79%, respectively. Even guidelines could not agree on a single cut-off value for the diagnosis of type 2 diabetes mellitus. The American Diabetic Association uses an A1C cut-off value of 6.5% while the recent Malaysian Clinical Practice Guidelines on the Management of Type 2 Diabetes Mellitus uses 6.3% for diagnosis. Lastly, although a study in the UK demonstrated that screening using A1C is more cost-effective than FBS in Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) cohort, generalization should not be made for our population, given the differences in prevalence of diabetes, age group, cut-off value of A1C, the cost and availability of the test locally.
format Conference or Workshop Item
author Shahar, Mohammad Arif
author_facet Shahar, Mohammad Arif
author_sort Shahar, Mohammad Arif
title Ten reasons why A1C should not be used as a screening tool for T2DM
title_short Ten reasons why A1C should not be used as a screening tool for T2DM
title_full Ten reasons why A1C should not be used as a screening tool for T2DM
title_fullStr Ten reasons why A1C should not be used as a screening tool for T2DM
title_full_unstemmed Ten reasons why A1C should not be used as a screening tool for T2DM
title_sort ten reasons why a1c should not be used as a screening tool for t2dm
publishDate 2017
url http://irep.iium.edu.my/58564/1/Debate%20HbA1C.pdf
http://irep.iium.edu.my/58564/
_version_ 1643615385398804480
score 13.211869

Similar Items